Advances in Food Technology and Nutritional Sciences

Open journal

ISSN 2377-8350

Hepatitis C Update

Omar Massoud*

Received: September 17th, 2015; Accepted: September 18th, 2015; Published: September 22nd, 2015

INTRODUCTION

The pace of Hepatitis C Virus (HCV) drug development in recent years has accelerated dramatically. But, for patients to benefit from these impressive advances, practitioners (i.e. “us”) need to know the most recent and accurate data on the diagnosis and treatment. In 2013, The American Association for Study of Liver Disease (AASLD) and the Infectious Disease Society of America (IDSA), put together web-based guidelines, which are frequently updated: www.hcvguidelines.org and www.aasld.org/practice-guidelines. 1 The size of the problem: In the USA, the prevalence is 1.8% (4.1 million), 80% of them are viremic. It is the principal cause of death from liver disease. It is the leading indication for liver transplantation in the USA. Although, HCV is a curable disease, it is under diagnosed and under-treated.2 Three quarters of individuals with HCV are unaware they are infected. 66-87% of patients diagnosed with HCV have not received antiviral treatment. Screening and diagnosis: 65-69% of anti-HCV positive patients were born between 1945 and 1964. Persons born between 1945 and 1964 had a 4.6 times higher prevalence of HCV than persons born prior to 1945 or after 1964 (3.7% vs. 0.73%).3 Treatment: Before treatment, you need to know: genotype and viral load, previous treatment, and presence of absence of cirrhosis.4 Generally speaking, 4 regimens are currently available. Ledipasvir/sofosbuvir × 12 weeks (8 weeks at discretion of practitioner), Paritaprevir/ritonavir/ombitasvir+dasabuvir + RBV × 12 weeks, Daclatasvir/sofosbuvir × 12 weeks and Sofusbuvir +Simeprevir±RBV × 12 weeks.5

HCV Genotype 1A

  • Daily (400 mg) daclatasvir (60 mg) and sofosbuvir for 12 weeks (no cirrhosis) or 24 weeks with or without weight-based RBV (cirrhosis).
  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.
  • Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis).
  • Daily simeprevir (150 mg) and sofosbuvir (400 mg) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis without the Q80K polymorphism) with or without weight-based RBV.

HCV Genotype 1B

  • Daily (400 mg) daclatasvir (60 mg) and sofosbuvir for 12 weeks (no cirrhosis) or 24 weeks with or without weight-based RBV (cirrhosis). Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.
  • Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV for 12 weeks.
  • Daily simeprevir (150 mg) and sofosbuvir (400 mg) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis) with or without weight-based RBV.

HCV Genotype 2

  • Daily sofosbuvir (400 mg) and weight-based RBV for 12 weeks.

HCV Genotype 4

  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.
  • Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) and weight-based RBV for 12 weeks.
  • Daily sofosbuvir (400 mg) and weight-based RBV for 24 weeks.

HCV Genotype 5&6

  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks.

 

Whom to Initiate HCV Therapy? Treatment is recommended for all patients with chronic HCV infection, except those with short life expectancies owing to comorbid conditions. Immediate treatment is assigned the highest priority for those patients with advanced fibrosis (Metavir stage F3), those with compensated cirrhosis (Metavir stage F4), liver transplant recipients, and patients with severe extrahepatic hepatitis C.

1. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. 2011; Accessed September 1, 2015.

2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2009; 49: 1335-1374.

3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714. doi: 10.7326/0003-4819-144-10-200605160-00004

4. Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? Antimicrob Chemother. 2008; 62(1): 1-4. doi: 10.1093/jac/dkn175

5. Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health. 2008; 98(5): 846-882. doi: 10.2105/AJPH.2007.113225

LATEST ARTICLES

Prevalence and Risk Factors of Subclinical Mastitis of Goats in Banadir Region, Somalia

Omar M. Salah*, Yasin H. Sh-Hassan, Moktar O. S. Mohamed, Mohamed A. Yusuf and Abas S. A. Jimale

doi.10.17140/VMOJ-9-184

Use of Black Soldier Fly (Hermetia illucens) Prepupae Reared on Organic Waste

Maggot Debridement Therapy: A Natural Solution for Wound Healing

Isayas A. Kebede*, Haben F. Gebremeskel and Gelan D. Dahesa,

doi.10.17140/VMOJ-9-183

Figure 11. Risk Map for the Introduction of Ruminant Diseases at Borders

Ovine Network in Morocco: Epizootics Spread Prevention and Identification of the At-Risk Areas for “Peste des Petits Ruminants” and “Foot and Mouth Disease”

Yassir Lezaar*, Mehdi Boumalik, Youssef Lhor, Moha El-Ayachi, Abelilah Araba and Mohammed Bouslikhane

doi.10.17140/EPOJ-8-131

The Impact of Family Dynamics on Palliative Care at the End-of-Life

Neil A. Nijhawan*, Rasha Mustafa and Aqeela Sheikh

doi.10.17140/PMHCOJ-10-154

Long-Term Follow-Up After Laparoscopic Radical Prostatectomy for Localized and Locally Advanced Prostate Cancer

Shrenik J. Shah*, Abhishek Jha, Chirag Davara, Rushi Mistry and Kapil Kachhadiya

doi.10.17140/UAOJ-7-147

Mindfulness, Sustained Attention and Post-Traumatic Stress in Tsunami Survivors

Christina Hagen*, Lars Lien, Edvard Hauff and Trond Heir

doi.10.17140/PCSOJ-2-115

Treatment and Control Methods of Bovine Mastitis: A Review

Isayas A. Kebede* and Gelan D. Dahesa

doi.10.17140/VMOJ-9-182

LATEST ARTICLES

Original Research

2024 Mar

Omar M. Salah*, Yasin H. Sh-Hassan, Moktar O. S. Mohamed, Mohamed A. Yusuf and Abas S. A. Jimale
Use of Black Soldier Fly (Hermetia illucens) Prepupae Reared on Organic Waste

review

2024 Mar

Isayas A. Kebede*, Haben F. Gebremeskel and Gelan D. Dahesa,